[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"adenocarcinoma-of-lung\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:adenocarcinoma-of-lung":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,51,95,118,141,168,190],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100641818","deep-learning-time-series-prediction-of-long-term-growth-patterns-of-pulmonary-ground-glass-nodules-using-serial-ct-100641818",false,"NCT07647692","Deep Learning Time-Series Prediction of Long-Term Growth Patterns of Pulmonary Ground-Glass Nodules Using Serial CT","Development and Multi-Cohort Validation of a Deep Learning Spatiotemporal Model for Predicting Long-Term Progression of Pulmonary Ground-Glass Nodules Using Serial Thoracic CT","GGN-Trajectory","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Persistent pulmonary ground-glass nodule (pGGN or mGGN, 5-30 mm) on thin-slice chest CT (slice thickness ≤ 1.5 mm).\n* Baseline and follow-up thin-slice chest CTs of sufficient quality for 3D segmentation and registration.\n* Minimum interval between any two consecutive CTs \\> 1 month.\n* Complete baseline clinical data available (age, sex, smoking history, family history of malignancy, relevant comorbidities).\n\nCohort-specific inclusion\n\n* Group 1 (Development): surgical resection of the target GGN at PKUPH between Jan 2007 - Jun 2025, with ≥ 2 pre-operative thin-slice CTs available.\n* Group 2 (Surgical internal test): surgical resection at PKUPH between Jul 2025 - Jan 2026, with ≥ 2 pre-operative thin-slice CTs available.\n* Group 3 (Non-surgical internal test): non-operative management at PKUPH between Jan 2020 - Dec 2025, with ≥ 3 thin-slice CTs of the target GGN available.\n* Group 4 (Prospective external validation): prospective enrollment after model lock at participating centers, baseline CT plus ≥ 2 planned routine follow-up thin-slice CTs.\n\nExclusion Criteria:\n\n* Coexisting severe pulmonary disease that obscures evaluation of the target GGN (e.g., active pulmonary tuberculosis, severe interstitial lung disease).\n* Prior history of any other thoracic malignancy, or active extrathoracic malignancy under treatment within 5 years, that would confound interpretation of the target GGN.\n* CT image quality insufficient for registration and feature extraction (severe motion artifact, slice thickness \\> 1.5 mm at any required timepoint, or extensive metallic artifact projecting over the target GGN).\n* Pure solid nodule with no ground-glass component.\n* Target GGN already received treatment (resection, ablation, or radiotherapy) prior to the baseline CT used in this study.","ALL","18 Years",{"count":20,"type":21},4750,"ESTIMATED","5 Years","OBSERVATIONAL","Pulmonary ground-glass nodules (GGNs) are commonly found on chest CT scans. Some stay stable for years, while others slowly or rapidly turn into lung cancer. Doctors currently follow these nodules with repeated CT scans, but it is difficult to tell ahead of time which nodules will progress, how fast they will progress, and which ones can be safely monitored rather than immediately treated.\n\nThis observational study aims to develop and validate an artificial intelligence (AI) model that uses each patient's series of CT scans over time to predict the long-term growth behavior of a GGN. The research team will collect three retrospective single-center cohorts from Peking University People's Hospital (a development cohort and two internal test cohorts, one from surgically resected patients and one from non-operated patients followed by serial CT) as well as a prospective multi-center validation cohort enrolled after the AI model is locked.\n\nFor every patient, each GGN is automatically segmented in three dimensions on every CT scan. A deep learning model extracts imaging features at each timepoint and feeds the sequence of features, together with the actual times between scans, into a time-aware sequence model. The model is trained to predict (i) whether the nodule will show radiological progression at 1, 3, and 5 years after baseline, and (ii) which of four long-term growth patterns the nodule will follow: stable, slow progression, slow-then-rapid progression, or rapid progression. In patients who were ultimately resected, the histopathological diagnosis serves as a secondary reference standard.\n\nThis is an observational study. No experimental treatment is given. All CT scans and clinical visits are part of routine clinical care.",[26,27,28],"Pulmonary Nodules","Lung Neoplasms","Adenocarcinoma of Lung",[30,31,32,33,34,35,36,37],"Ground Glass Opacity","Ground-Glass Nodule","Longitudinal CT","Time-Series Analysis","Growth Trajectory","Volume Doubling Time","Deep Learning","Radiomics","NOT_YET_RECRUITING","2026-06-10",{"date":41,"type":42},"2026-06-15","ACTUAL",{"date":44,"type":21},"2026-06-01",{"date":46,"type":21},"2031-06-01",{"name":48,"class":49},"Peking University People's Hospital","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":67,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":94},"100474311","phase-2-a-study-of-lp-300-with-carboplatin-and-pemetrexed-in-never-smokers-with-advanced-lung-adenocarcinoma-100474311","NCT05456256","A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma","Phase II Trial of LP-300 in Combination With Carboplatin and Pemetrexed in Never Smoker Patients With Relapsed Advanced Primary Adenocarcinoma of the Lung After Treatment With Tyrosine Kinase Inhibitors (The HARMONIC Study)","HARMONIC","Inclusion Criteria:\n\n1. Patients with confirmed histopathological diagnosis of inoperable advanced (Stage III or IV) primary adenocarcinoma (including bronchioalveolar cell carcinoma) of the lung with specific actionable genomic alterations (e.g., mesenchymal epithelial transition (MET) exon14 skipping mutations, anaplastic lymphoma kinase (ALK), epidermal growth factor receptor (EGFR), neurotrophic tyrosine receptor kinase (NTRK) fusions, etc.). If pathological or radiological findings are inconclusive for a diagnosis of primary adenocarcinoma of the lung, additional studies must be performed to confirm primary lung versus metastatic adenocarcinoma. Patients with no known actionable genomic alterations are ineligible to enroll in the study.\n2. Locally advanced inoperable or metastatic lung cancer.\n3. Patients must be never smokers: a never smoker is an adult who has never smoked, or who has smoked less than 100 cigarettes (or equivalent in other products such as vapes, cigars, pipes, hookahs, and marijuana use) in his or her lifetime. Note: a patient with actionable genomic alteration(s) who is a former smoker may be enrolled if such a patient would ordinarily be treated with pemetrexed and carboplatin combination based on institutional standard clinical practice; consultation with the sponsor's Medical monitor would be required\n4. Patients who have received systemic treatment with tyrosine kinase inhibitors (TKIs) for non-small cell lung cancer but have experienced disease progression, unacceptable TKI-related toxicities, or are unable to tolerate the further use of TKIs.\n5. Prior radiation therapy is allowed, provided (1) that at least one area of measurable tumor (by computed tomography (CT) scan with at least one target lesion) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 that has not been subject to prior irradiation, and (2) that any such therapy is completed and any radiation-induced sequelae are recovered at least 21 days before randomization.\n6. Patients with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n7. Patients who are at least 18 years of age.\n8. Patients with documented stable central nervous system (CNS) metastases with no cognitive deficits, or progressive sensory or motor deficits, or seizures during the last 21 days prior to enrollment are eligible. Patients must have discontinued anti-seizure medications and steroids at least 14 days prior to patient enrollment.\n9. Patients must have fully recovered from any prior major surgical or diagnostic staging procedure (e.g., thoracotomy, mediastinoscopy), and have a post-operative status of at least 30 days before enrollment.\n10. Patients must have adequate bone marrow, adequate hepatic function, and baseline creatinine levels documented by specific laboratory criteria within 21 days prior to enrollment, including the following:\n\n    * White blood cell count ≥ 2 x 10\\*9\u002FL\n    * Absolute neutrophil count (ANC) ≥ 1.5 x 10\\*9\u002FL\n    * Hemoglobin ≥ 10 g\u002FdL\n    * Platelet count ≥ 100 x 10\\*9\u002FL\n    * Total bilirubin \\\u003C 1.5 x the upper limit of normal (ULN). For patients with Gilbert's syndrome, total bilirubin \\\u003C 2.5 x ULN\n    * Aspartate aminotransferase\u002F serum glutamic oxaloacetic transaminase (AST\u002FSGOT) ≤ 2.5 x ULN\n    * Alanine aminotransferase\u002F serum glutamic pyruvic transaminase (ALT\u002FSGPT) ≤ 2.5 x ULN\n    * Alkaline phosphatase ≤ 2.5 x ULN\n    * Baseline serum creatinine level no greater than 1.5 mg\u002FdL or 133 μmol\u002FL.\n    * Creatinine clearance ≥ 45 mL\u002Fmin as calculated using the Cockcroft-Gault methodology (Cockcroft 1976)\n    * Magnesium ≥ 1.7 mg\u002FdL\n11. Female patients of child-bearing potential must have a negative pregnancy test and must agree to use an acceptable contraceptive method during the study and for 12 weeks after their last dose of study treatment. Male patients with partners of child-bearing potential must also agree to use an adequate method of contraception for the duration of the study and for 12 weeks after their last dose of study treatment.\n\n    Note: a) A patient is considered of childbearing potential if she is biologically capable of having children and is sexually active. Medically acceptable contraceptives include: (1) surgical sterilization (such as a tubal ligation, hysterectomy, or vasectomy), (2) approved hormonal contraceptives (such as birth control pills, patches, implants or injections), (3) barrier methods (such as a condom or diaphragm) used with a spermicide (only if used in combination with another mentioned method), or (4) an intrauterine device (IUD). Contraceptive measures and other medications sold for emergency use after unprotected sex, are not acceptable methods for routine use. If a female patient becomes pregnant, study therapy must be discontinued immediately. Lastly, b) the period for use of contraception after last dose of pemetrexed or carboplatin should be determined by the domestic drug labels and\u002For institutional standard clinical practice. For S Korea, contraception is to be used for 6 months after the last dose.\n12. Patients must have been disease-free at least two years for other malignancies, excluding:\n\n    * Curatively-treated basal cell carcinoma,\n    * Ductal carcinoma in situ (DCIS) of the breast\n    * Non-melanomatous carcinoma of the skin, or\n    * Carcinoma in situ of the cervix.\n13. Be willing to provide an archival tumor tissue sample, if available. The archival sample must be from a tumor lesion that was not previously irradiated. Formalin-fixed, paraffin embedded (FFPE) tissue blocks are preferred to slides. The sample must have been obtained less than 36 months prior to consent.\n14. Provide signed, written, Institutional Review Board (IRB) approved informed consent prior to any screening procedures.\n\nExclusion Criteria:\n\n1. Patients with small cell, squamous cell, large cell, undifferentiated, mesothelioma, or any form of mixed (e.g., small cell and adenocarcinoma or squamous and adenocarcinoma) histopathological diagnosis of primary lung cancer.\n2. Patients with metastatic adenocarcinoma arising from any primary site other than the lung.\n3. Patients who have received any prior investigational agents except for investigational TKI drugs. The minimum drug washout period for all TKIs, including approved and investigational, is ≥ 5 half-lives or 2 weeks, whichever is shorter.\n4. Patients who have received chemotherapy and\u002For immunotherapy but transitioned to a TKI with no evidence of disease progression will be allowed to enroll. Patients who experienced disease progression while on chemotherapy and\u002For immunotherapy will be ineligible for the trial.\n5. Patients taking medications that are sensitive substrates of CYP2C19 or P-gp transporters\n6. Patients with recent onset (within 6 months of randomization) of congestive heart failure (New York Heart Association Classification Class II or greater), angina pectoris, unstable angina pectoris, serious uncontrolled cardiac arrhythmias, myocardial infarction, stroke, or transient ischemic attacks.\n7. Have a corrected QT interval (using Fridericia's correction formula) (QTcF) of \\> 470 msec. (average of triplicate ECGs) at Screening and\u002For on C1D1 (pre- dose) except for a documented bundle branch block or unless secondary to pacemaker. In the case of a documented bundle branch block or a pacemaker, discussion with the Medical Monitor is required prior to enrollment.\n8. Patients with unstable CNS metastases (characterized by progressive sensory\u002Fmotor impairment, cognitive\u002Fspeech impairment, or seizure activity) within 21 days before enrollment.\n9. Patients who do not have at least one (1) measurable disease site that has not been previously irradiated.\n10. Patients who are known to be positive for human immunodeficiency virus (HIV), hepatitis B virus surface antigen (HbsAg) or hepatitis C virus (HCV).\n11. Patients with active infections, active interstitial lung disease, uncontrolled high blood pressure, uncontrolled diabetes mellitus, uncontrolled seizures (not due to CNS metastases) within the last 3 months, or other serious underlying medical condition.\n12. Patients with documented hypersensitivity to any of the study medications (LP-300, pemetrexed, carboplatin and\u002For excipients) or supportive agents that may be used.\n13. Patients who are pregnant or are breastfeeding.\n14. Patients who have undergone blood transfusions within 10 days before randomization.\n15. Any other medical intervention or other condition which, in the opinion of the Principal Investigator, could compromise adherence to study requirements or confound the interpretation of study results.\n16. Patients who have a life expectancy of less than 3 months.",{"count":60,"type":21},90,"INTERVENTIONAL",[63],"PHASE2","The goal of this clinical trial is to determine clinical advantages for LP-300 in combination with carboplatin and pemetrexed in the never smoker patient population. The primary objectives of this study are to determine progression-free survival (PFS) and overall survival (OS) in the study-defined patient population when LP-300 is co-administered with the standard of care chemotherapy drugs carboplatin and pemetrexed compared to carboplatin and pemetrexed alone. This has been designed as a multicenter, open label, phase II trial with 90 patients to be enrolled in the United States.",[28,66],"Carcinoma, Non-Small-Cell Lung",[68,69,70,71,72,73,74,75,76,77,78,79,80,81,82],"never smoker","non smoker","EGFR","ALK","ROS","MET","tyrosine kinase inhibitor","TKI","pemetrexed","carboplatin","NSCLC","never-smoker","non-smoker","TK inhibitor","lung cancer","RECRUITING","2026-04-28",{"date":86,"type":42},"2026-05-04",{"date":88,"type":42},"2023-03-01",{"date":90,"type":21},"2027-06",{"name":92,"class":93},"Lantern Pharma Inc.","INDUSTRY",16,{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":103,"conditions":104,"keywords":106,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":50},"100490390","using-biomarkers-for-diagnosis-risk-stratification-of-post--treatment-recurrence-and-long-term-surveillance-of-lung-cancer-100490390","NCT05665504","Using Biomarkers for Diagnosis, Risk Stratification of Post -Treatment Recurrence and Long-Term Surveillance of Lung Cancer","Inclusion Criteria:\n\n* Potentially-resectable lung nodule 8-40 mm diameter suspected (no preop diagnosis) of being a clinically node-negative lung cancer \\[clinical stage IA-IB (cT1a-T2aN0), \\\u003C4cm diameter\\].\n* If surgical resection is recommended, patient will undergo surgery at Moffitt Cancer Center.\n* If a definite tissue diagnosis is obtained and stereotactic body radiotherapy (SBRT) is the recommended treatment instead of surgery, the SBRT will be delivered at Moffitt Cancer Center.\n* \\>18 years old, male or female.\n* ECOG performance status 0-1.\n* Agree to participate in the follow-up protocol.\n* Any suspected primary lung cancer cell type (except a suspected typical carcinoid tumor, carcinoma in situ or minimally-invasive carcinoma).\n* Ability to understand and the willingness to sign a written, informed consent document.\n\nExclusion Criteria:\n\n* Participants who are actively receiving any cancer treatment.\n* Participants with uncontrolled intercurrent illness.\n* Prior lung cancer within 5 years.\n* Current active other major cancer except non-melanoma skin cancer.\n* Patients with pure ground glass opacities (nodules) or hilar masses.\n* Suspected typical carcinoid cell type (well-differentiated neuroendocrine carcinoma).\n* Metastatic nodule (suspected) in the lung from an extrapulmonary cancer.\n* Patient unable to provide informed consent.\n* Prisoner or incarcerated individual.\n* For surgical patients, a R1 or R2 resection.",{"count":102,"type":21},250,"This study is an observational study of blood and tissue biomarkers. Investigators plan to evaluate the accuracy of lung cancer biomarkers found in the blood in determining if a lung nodule is cancer or benign. Investigators also plan to examine another biomarker found in the tumor tissue to identify participants after lung cancer surgery who have a high risk for recurrent cancer. Finally, investigators plan to determine if one of the blood-based biomarkers can be used to detect any late cancer recurrence.",[105,28],"Lung; Node",[107,108],"Biomarkers","Lung Cancer Biomarkers","2026-03-31",{"date":111,"type":42},"2026-04-01",{"date":113,"type":42},"2023-01-11",{"date":115,"type":21},"2028-02",{"name":117,"class":49},"H. Lee Moffitt Cancer Center and Research Institute",{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":4,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":125,"targetDuration":4,"studyType":61,"phases":127,"briefSummary":128,"conditions":129,"keywords":4,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":140},"100370586","phase-2-rmt-in-combination-with-durvalumab--chemo-in-untreated-adenocarcinoma-nsclc-a-randomized-double-blind-phase-ii-trial-100370586","NCT04105270","RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial","A Randomized Double Blind Phase II Trial of Restorative Microbiota Therapy (RMT) in Combination With Durvalumab (MEDI4736) and Chemotherapy in Untreated Patients With Advanced or Metastatic Adenocarcinoma Non-Small Cell Lung Cancer","Inclusion Criteria:\n\n* Histologically or cytologically confirmed adenocarcinoma of the lung that is unresectable stage IIIB\u002FC or stage IV, does not have an EGFR sensitizing (activating) mutation or ALK or ROS1 translocation. BRAF, RET, NTRK, MET ex 14 splice site mutation\n* Measurable disease based on RECIST 1.1\n* Tumor sample requirements\n\n  * Mandatory provision of an unstained, archived tumor tissue sample in a quantity sufficient to allow for biomarker and genomic analysis. A minimum of 10 unstained slides should be available for evaluation.\n  * Known PD-L1 TC expression status assayed by Ventana SP263. Patients who have known PDL-1 as assayed by PharmDx 22C3 assay may be eligible; however, available archival tissue will be used to assay with Ventana SP263 test.\n* Prior chemotherapy or immunotherapy as adjuvant therapy for lung cancer is permitted as long as it has been \\>6 months from last dose at the time of enrollment. Local treatment of isolated lesions, excluding target lesions, for palliative intent is acceptable (e.g. by local surgery or radiotherapy). Prior systemic therapy for advanced\u002Fmetastatic NSCLC makes the patient ineligible for this study.\n* Patients with treated brain metastasis are eligible as long as they have stable symptoms, are more than 2 weeks from completion of therapy, and do not require more than 10mg of daily prednisone or equivalent.\n* ECOG Performance status of 0 or 1\n* Body weight of \\>30 kg\n* Adequate organ function within 14 days of study enrollment defined as:\n\n  * Hemoglobin ≥ 9.0 g\u002FdL\n  * Absolute neutrophil count ≥1,500\u002FmcL\n  * Platelets ≥ 100,000\u002FmcL\n  * Total bilirubin ≤1.5x upper limit of normal (ULN) - this will not apply to patients with confirmed Gilbert's syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or hepatic pathology), who will be allowed only in consultation with their physician.\n  * AST (SGOT) and ALT (SGPT) ≤2.5 x institutional ULN unless liver metastases are present, in which case it must be ≤5x ULN\n  * Measured creatinine clearance (CL) \\>40 mL\u002Fmin or calculated creatinine CL\\>40 mL\u002Fmin by the Cockcroft-Gault formula (Cockcroft and Gault 1976) or by 24-hour urine collection for determination of creatinine clearance:\n* Expected life expectancy of at least 12 weeks in the opinion of the enrolling investigator as documented in the medical record\n* Women of childbearing potential and men with partners of child-bearing potential must agree to use effective contraception for the time of screening to the duration of treatment and 3 months after the last dose of study drug\n* Provide voluntary written consent prior to the performance of any research related tests or procedures.\n\nExclusion Criteria:\n\n* Not pregnant or breast feeding. Evidence of post-menopausal status, or negative urine or serum pregnancy test for female pre-menopausal patients. Women will be considered postmenopausal if they have amenorrhea for 12 months without an alternative medical explanation\n* Dysphagia or inability to swallow medications\n* Squamous cell, large cell, or NSCLC NOS (not otherwise specified) histology or mixed tumors\n* Has untreated brain metastasis or active leptomeningeal carcinomatosis\n* Has a known sensitivity to any component of therapeutic agents used in this study\n* Receipt of any immunotherapy or investigational drug within 4 weeks prior to the first dose of study drug; and in the case of monoclonal antibodies 6 weeks prior to the first dose of study drug\n* Prior treatment with any other anti-PD-1, or PD-L1, including durvalumab or an anti-PD-L2 agent or an antibody or a small molecule targeting other immuno-regulatory receptors except as adjuvant therapy for NSCLC so long as it has been greater than six months since the last treatment\n* Current or prior use of immunosuppressive medication within 28 days before the first dose of study drug, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg\u002Fday of prednisone, or an equivalent corticosteroid\n* Recent major surgery within 4 weeks prior to entry into the study (excluding the placement of vascular access) that would prevent administration of study drug\n* Active or prior documented autoimmune disease within the past 2 years requiring systemic treatment (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Patients with vitiligo, Grave's disease, or psoriasis not requiring systemic treatment (within the past 2 years) are not excluded. Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.\n* Active documented inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis) who require immunosuppression or patients who exceed 10 mg\u002Fday of prednisone, or an equivalent corticosteroid are excluded\n* History of primary immunodeficiency\n* History of organ transplant that requires therapeutic immunosuppression\n* Taking daily probiotics (patients with last probiotic \\> 4weeks prior to first dose of RMT are eligible)\n* History of Human Immunodeficiency Virus (HIV) (known HIV 1\u002F2 antibodies positive) who are on anti-retroviral treatment for \\\u003C 6 months and absolute CD4 count\\\u003C500 (patients with HIV not meeting these criteria are eligible)\n* Has known active Hepatitis B or C. Active Hepatitis B is defined as a known positive HBsAg, and positive hepatitis B virus quantification assay (patients with history of Hepatitis B who have seroconversion i.e. Hepatitis B core antibody positive and Hepatitis B surface antibody positive are eligible). Active Hepatitis C is defined by a known positive Hep C Ab result and positive quantitative HCV RNA results (Patients with Hepatitis C who are on anti-viral suppressive therapy and negative quantitative HCV RNA results are eligible)\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease or gastritis, active bleeding diatheses\n* Myocardial infarction or stroke within 3 months prior to enrollment\n* History of systolic or diastolic heart failure with New York Heart Association (NYHA) class III or IV symptoms (refer to Appendix II)\n* Has active or prior history of (non-infectious) pneumonitis that required steroids or patients with interstitial lung disease\n* Psychiatric illness\u002Fsocial situations that would limit compliance with study requirements or compromise the ability of the patient to give written informed consent\n* Known history of active tuberculosis. Patients with prior history of latent TB could be included if they have been treated previously with isoniazid.\n* Patients who are on chronic systemic antibiotic therapy (antibiotics for ≥60 consecutive days within 12 weeks of enrollment). Patients who receive systemic antibiotics between enrollment and start of RMT are eligible\n* Receipt of live attenuated vaccination within 30 days prior to study entry or within 30 days of receiving RMT\n* History of another primary malignancy (excluding non-melanoma skin cancer) within 5 years prior to starting RMT, except if the patient has undergone potentially curative therapy with no evidence of disease recurrence for 5 years since initiation of that therapy\n* Any condition that, in the opinion of the investigator, would interfere with evaluation of the study drug or interpretation of patient safety or study results",{"count":126,"type":21},82,[63],"This is a randomized, active-controlled, parallel-group, double-blind Phase II trial, of oral restorative microbiota therapy (RMT) or placebo combined with intravenous (IV) durvalumab (MEDI4736) plus chemotherapy in patients with treatment naïve advanced or metastatic adenocarcinoma non-small cell lung cancer (NSCLC)",[28,130],"Lung Cancer","2025-09-10",{"date":133,"type":42},"2025-09-11",{"date":135,"type":42},"2022-11-30",{"date":137,"type":21},"2028-01",{"name":139,"class":49},"Masonic Cancer Center, University of Minnesota",10,{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":145,"acronym":146,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":148,"targetDuration":4,"studyType":61,"phases":150,"briefSummary":152,"conditions":153,"keywords":155,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":50},"100577324","bioimpedance-analysis-in-perioperative-assessment-in-thoracic-surgery-100577324","NCT06796816","Bioimpedance Analysis in Perioperative Assessment in Thoracic Surgery","BIVA-18","Inclusion Criteria:\n\n\\- Patients undergoing pulmonary resection surgery for primary neoplasm within a one-year timeframe.\n\nExclusion Criteria:\n\n* Patients with chronic atrial fibrillation (AF).\n* Patients who have previously undergone major pulmonary resection.\n* Patients with pacemakers or implantable devices, as the use of bioimpedance vector analysis (BIVA) may be contraindicated.",{"count":149,"type":21},1000,[151],"NA","The assessment of surgical and postoperative risks in thoracic surgery is a field of significant interest because the surgical procedure causes substantial changes in the body's homeostasis.\n\nThe postoperative course is characterized by considerable clinical variability compared to the preoperative classification, which highlights more homogeneous data among various patient groups. This variability appears to result from individual differences in response to extensive pulmonary resections. Notably, the homogeneity of preoperative data does not correlate with the greater variability observed in the postoperative course.\n\nThe application of algorithms derived from BIVA in bioimpedance studies has proven particularly useful for prognostic assessments in oncology, as it can evaluate a patient's hydration status and muscle reserves at the time of diagnosis or the start of clinical\u002Fsurgical treatment.\n\nUnderstanding body composition, particularly the quantity and\u002For quality of muscle mass, is essential for diagnosing sarcopenia.\n\nBy passing a low-intensity alternating current (imperceptible to the patient) through the body, BIVA measures provide insights into body water distribution (both intracellular and extracellular), lean mass and skeletal muscle mass. Overall, the test offers a detailed picture of hydration status and skeletal muscle composition.\n\nAnother validated tool for assessing sarcopenia, which provides information on both muscle quantity (via cross-sectional area measurements) and muscle quality (via muscle density measurements), is computed tomography (CT). CT imaging is typically performed for diagnostic and staging purposes before surgery in thoracic surgery patients, either alone or in combination with positron emission tomography (PET).\n\nOur study will focus on assessing correlations between clinical, imaging, and bioimpedance data and postoperative outcomes, with particular attention to the incidence of atrial fibrillation (AF), pulmonary atelectasis requiring treatment, and increased pleural drainage production.\n\nAdditionally, we will evaluate the relationship between the surgical approach (open surgery vs. video-assisted thoracoscopic surgery, or VATS) and short-term bioimpedance values.",[154,28],"Lung Resection",[156,82,157],"bioimpedence","sarcopenia","2025-01-22",{"date":160,"type":42},"2025-01-28",{"date":162,"type":42},"2019-04-02",{"date":164,"type":21},"2026-12",{"name":166,"class":167},"Azienda USL Reggio Emilia - IRCCS","OTHER_GOV",{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":4,"eligibilityCriteria":174,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":175,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":177,"conditions":178,"keywords":179,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":50},"100549999","differentiating-the-invasiveness-of-lung-adenocarcinoma-by-dual-energy-ct-parameter-100549999","NCT06441357","Differentiating the Invasiveness of Lung Adenocarcinoma by Dual Energy CT Parameter","Differentiating the Invasiveness of Lung Adenocarcinoma by Dual Energy CT Using Extracellular Volume Measured in Delay Phase","Inclusion Criteria:\n\n* patients older than 18 years old with pulmonary nodules (diameter≤3 cm).\n* pathologically confirmed as lung adenocarcinoma.\n* without history of other malignancies.\n* accurate hematocrit within 1 week before contrast enhanced dual energy CT examination.\n\nExclusion Criteria:\n\n* with a history of allergy to iodine contrast agents and other reasons who are unable to complete the examination.\n* without histopathology of invasion stage, such as AAH, AIS, MIA and IAC.\n* history of chemotherapy, radiotherapy, or other anti-tumor therapy before contrast enhanced dual energy CT.\n* poor image quality.\n* contrast enhanced dual energy CT scans ≥ 4 weeks before surgery.",{"count":176,"type":21},2000,"The core purpose of this study is to investigate whether the extracellular volume (ECV) fraction measured in delay phase by dual energy computed tomography (DECT) can distinguish precancerous lesions from early-stage lung adenocarcinomas, which could assist clinical decision making for surgery operation indication and strategy.",[28],[180],"ECV, invasion, lung adenocarcinoma, DECT","2024-05-28",{"date":183,"type":42},"2024-06-04",{"date":185,"type":21},"2024-06-01",{"date":187,"type":21},"2026-06-30",{"name":189,"class":49},"Tang-Du Hospital",{"id":191,"slug":192,"hasResults":11,"nctId":193,"briefTitle":194,"officialTitle":194,"acronym":4,"eligibilityCriteria":195,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":196,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":198,"conditions":199,"keywords":202,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":50},"100481588","apollo-11-consortium-of-italian-centers-involved-in-treatment-of-patients-with-lung-cancer-treated-with-innovative-therapies-real-world-data-and-translational-reaserch-100481588","NCT05550961","APOLLO 11, Consortium of Italian Centers Involved in Treatment of Patients With Lung Cancer Treated With Innovative Therapies: Real World Data and Translational Reaserch","Inclusion Criteria:\n\n1. Provision of signed and dated written informed consent, when applicable, by the patient or legally acceptable representative prior to any mandatory study-specific procedures, sampling, and analyses;\n2. Patients must be ≥18 years of age at the time of signing the informed consent;\n3. Histologically or cytologically confirmed lung cancer (NSCLC or SCLC) at any stage (I-IV) candidate to receive or already treated with innovative therapies (ICIs, target therapies and next generation therapies).\n\nExclusion Criteria:\n\n1. Patients who are or will be taking other unapproved antineoplastic therapies concurrently are not eligible.\n2. Patients who have not received an oncological systemic innovative therapy at any setting\n3. Patients received only local treatments (e.g., only surgery, or only radiotherapy)\n4. Patients who received only standard chemotherapy are excluded.\n5. Patients who received treatment therapies before 2010 are excluded.",{"count":197,"type":21},1200,"APOLLO 11 main aim is to build a strong Italian long-lasting lung cancer network (in around 48 Italian centres) on real world data and translational research by creating a decentralized long-term national database (settle locally in each centre) and a \"virtual\" multilevel biobank in each centre. Besides, APOLLO 11 will take advantage of the translational research joint effort with the credo \"unity is strength\".",[78,200,130,28,201],"Cancer","Squamous Cell Lung Cancer",[203,204,205,206],"#NSCLC","#Immunotherapy","#Targeted Therapy","#Artificial Intelligence","2023-10-17",{"date":209,"type":42},"2023-10-23",{"date":211,"type":42},"2022-10-01",{"date":213,"type":21},"2032-10-01",{"name":215,"class":49},"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano"]